Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)

被引：0

作者：

Maubec, E. ^{[1
]}

Boubaya, M. ^{[2
]}

Deschamps, L. ^{[3
]}

Beylot-Barry, M. ^{[4
]}

Petrow, P. ^{[5
]}

Scheer-Senyarich, I. ^{[1
]}

Basset-Seguin, N. ^{[6
]}

Marqueste, C. Gaudy ^{[7
]}

Quereux, G. ^{[8
]}

Bloch-Queyrat, C. ^{[9
]}

Leccia, M-T. ^{[10
]}

Stefan, A. ^{[11
]}

Saiag, P. ^{[12
]}

Grange, F. ^{[13
]}

Meyer, N. ^{[14
]}

Rat, S. Dalac ^{[15
]}

Alloux, C. ^{[16
]}

Lopez, I. ^{[17
]}

Tibi, A. ^{[16
]}

Levy, V. ^{[18
]}

机构：

[1] Hop Avicenne, AP HP, Dermatol Dept, Bobigny, France

[2] Hop Avicenne, AP HP, Unite Rech Clin, Bobigny, France

[3] Hop Bichat Claude Bernard, APHP, Pathol, Paris, France

[4] CHU Bordeaux, Dermatol Dept, Hop St Andre, Bordeaux, France

[5] Polyclin St Come, Radiol, Compiegne, France

[6] Hop St Louis, AP HP, Paris, France

[7] CHU La Timone Enfants, AP HM, Dermatol Dept, Marseille, France

[8] CHU Nantes Hotel Dieu, Dermatol, Nantes, France

[9] Hop Avicenne, AP HP, Res Clin Unit, Bobigny, France

[10] CHU Grenoble Alpes, Dermatol, Site Nord La Tronche, La Tronche, France

[11] CHU Caen, Dermatol, Hop Cote Nacre, Caen, France

[12] Hop Ambroise Pare, AP HP, Dermatol & Oncol Dept, Boulogne, France

[13] Ctr Hosp Valence, Dermatol, Valence, France

[14] Ctr Hosp Univ Toulouse, Dermatol, Hop Larrey, Toulouse, France

[15] CHU Dijon, Dermatol, Dijon, France

[16] APHP, Pharm, Agence Gen Equipements & Prod Sante, Paris, France

[17] Polyclin St Come Assoc Cabinet Radiol & Imagerie, Radiol, Compiegne, France

[18] Hop Avicenne, Clin Res, Bobigny, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2273

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1139P

引用

页码：S682 / S683

页数：2

共 50 条

[1] Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas
Maubec, Eve
Boubaya, Marouane
Petrow, Peter
Beylot-Barry, Marie
Basset-Seguin, Nicole
Deschamps, Lydia
Grob, Jean-Jacques
Dreno, Brigitte
Scheer-Senyarich, Isabelle
Bloch-Queyrat, Coralie
Leccia, Marie-Therese
Stefan, Andreea
Saiag, Philippe
Grange, Florent
Meyer, Nicolas
de Quatrebarbes, Julie
Dinulescu, Monica
Legoupil, Delphine
Machet, Laurent
Dereure, Olivier
Zehou, Ouidad
Montaudie, Henri
Wierzbicka-Hainaut, Ewa
Le Corre, Yannick
Mansard, Sandrine
Guegan, Sarah
Arnault, Jean-Philippe
Dalac, Sophie
Aubin, Francois
Alloux, Celine
Lopez, Isabelle
Cherbal, Soufian
Tibi, Annick
Levy, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) : 3051 - 3061
[2] Final results of CA209-9JC: A phase II study of first-line nivolumab in patients with advanced cutaneous squamous cell carcinoma
Ramella Munhoz, R.
de Camargo, V. P.
Nader Marta, G.
Queiroz, M. M.
Cury-Martins, J.
Nardo, M.
Chaul-Barbosa, C.
Ricci, H.
de Mattos, M. R.
de Menezes, T. A. F.
Machado, G. U. D. C.
Bertolli, E.
Barros, M.
Franke, F. A.
Ferreira, F. D. O.
Feher, O.
de Castro, G., Jr.
ANNALS OF ONCOLOGY, 2021, 32 : S885 - S885
[3] Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer
Taniguchi, Hirokazu
Yamaguchi, Hiroyuki
Dotsu, Yosuke
Shimada, Midori
Gyotoku, Hiroshi
Senju, Hiroaki
Takemoto, Shinnosuke
Kitazaki, Takeshi
Fukuda, Masaaki
Ogawara, Daiki
Soda, Hiroshi
Nakatomi, Katsumi
Sugasaki, Nanae
Kinoshita, Akitoshi
Nagashima, Seiji
Ikeda, Takaya
Nakamura, Yoichi
Sakamoto, Noriho
Obase, Yasushi
Fukuda, Minoru
Mukae, Hiroshi
THORACIC CANCER, 2019, 10 (09) : 1764 - 1769
[4] Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas
Maubec, Eve
Boubaya, Marouane
Deschamps, Lydia
Beylot-Barry, Marie
Petrow, Peter
Scheer-Senyarich, Isabelle
Basset-Seguin, Nicole
Grob, Jean-Jacques
Dreno, Brigitte
Bloch-Queyrat, Coralie
Leccia, Marie Therese
Stefan, Andreea Raluca
Saiag, Philippe
Grange, Florent
Meyer, Nicolas
Dalac, Sophie
Alloux, Celine
Lopez, Isabelle
Tibi, Annick
Levy, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Cetuxintab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study
Maubec, E.
Petrow, P.
Duvillard, P.
Laouenan, C.
Duval, X.
Lacroix, L.
Bagot, M.
Faivre, S. J.
Mentre, F.
Avril, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.
Maubec, Eve
Boubaya, Marouane
Petrow, Peter
Basset-Seguin, Nicole
Grob, Jean Jacques
Dreno, Brigitte
Beylot-Barry, Marie
Scheer-Senyarich, Isabelle
Helfen, Sabine
Leccia, Marie Therese
Stefan, Andreea Raluca
Saiag, Philippe
De Quatrebarbes, Julie
Meyer, Nicolas
Deschamps, Lydia
Alloux, Celine
Lopez, Isabelle
Cherbal, Soufian
Tibi, Annick
Levy, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
Szczylik, C.
Demkow, T.
Staehler, M.
Rolland, F.
Negrier, S.
Hutson, T. E.
Bukowski, R. M.
Scheuring, U. J.
Burk, K.
Escudier, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[8] Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
Jin, Ramon
Park, Haeseong
Wang-Gillam, Andrea
Suresh, Rama
Rigden, Caron E.
Amin, Manik A.
Tan, Benjamin R.
Pedersen, Katrina
Lim, Kian-Huat
Trikalinos, Nikolaos
Acharya, Abhi
Copsey, Megan
Navo, Katie
Morton, Ashley
Gao, Feng
Lockhart, A. Craig
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results
Saltos, Andreas Nicholas
Tanvetyanon, Tawee
Creelan, Ben C.
Shafique, Michael Rahman
Antonia, Scott Joseph
Haura, Eric B.
Zheng, Hong
Yu, Xiaoqing
Saller, James Joseph
Viracacha, Sebastian
Thapa, Ram
Boyle, Theresa A.
Chen, Dung-Tsa
Beg, Amer A.
Gray, Jhanelle Elaine
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.
Lopez Vivanco, Guillermo
Carrera, Sergio
Rubio, Itziar
Azcona, Eider
Sancho, Aintzane
Calvo, Begona
Buque, Aitziber
Aresti, Unai
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →